RT Journal Article
SR Electronic
T1 Therapeutic Innovations for Targeting Childhood Neuroblastoma: Implications of the Neurokinin-1 Receptor System
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 5911
OP 5918
VO 37
IS 11
A1 MICHAEL BERGER
A1 DIETRICH VON SCHWEINITZ
YR 2017
UL http://ar.iiarjournals.org/content/37/11/5911.abstract
AB Neuroblastoma is the most common solid extracranial malignant tumor in children. Despite recent advances in the treatment of this heterogenous tumor with surgery and chemotherapy, the prognosis in advanced stages remains poor. Interestingly, neuroblastoma is one of the few solid tumors, to date, in which an effect for targeted immunotherapy has been proven in controlled clinical trials, giving hope for further advances in the treatment of this and other tumors by targeted therapy. A large array of novel therapeutic options for targeted therapy of neuroblastoma is on the horizon. To this repεrtoirε, the neurokinin-1 receptor (NK1R) system was recently added. The present article explores the most recent developments in targeting neuroblastoma cells via the NK1R and how this new knowledge could be helpful to create new anticancer therapies agains neuroblastoma and other cancers.